All Stories

  1. Correction: Zupo et al. Dietary Intake of Polyphenols and All-Cause Mortality: A Systematic Review with Meta-Analysis. Metabolites 2024, 14, 404
  2. Clinically Assessed Tooth Loss and Malnutrition Risk in U.S. Older Adults
  3. Advancements in longevity pharmacology research – are we finally seeing clinical progression?
  4. Association Between Language Performance and Functional Status in Patients with Neurocognitive Disorders
  5. Machine learning-assisted resting-state electroencephalography improves diagnostic accuracy in psychiatric disorders: A narrative review
  6. Gustatory dysfunction and oral frailty: Emerging implications for Alzheimer's disease
  7. Associations among self-reported oral health and intrinsic capacity domains in U.S. older adults: analysis from NHANES 2009–2014
  8. Association between periodontal disease and intrinsic capacity in older adults: insights from NHANES 2009–2014
  9. The therapeutic potential of thalassotherapy for enhancing well-being and reducing pharmaceutical costs in individuals with disabilities
  10. Novel approaches for the treatment of frontotemporal dementia: is there hope for the future?
  11. Alzheimer's Disease May Benefit from Olive Oil Polyphenols: A Systematic Review on Preclinical Evidence Supporting the Effect of Oleocanthal on Amyloid-β Load
  12. Corrigendum to “Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence” [Biomed. Pharmacother. 188 (2025) 118199]
  13. Targeting oral frailty indicators of late-life cognitive disorders and depression: a systematic review
  14. Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: the challenges ahead
  15. The Effect of a Mediterranean Diet on Arterial Stiffness: A Systematic Review
  16. An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
  17. Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders
  18. The Biological Rationale for Integrating Intrinsic Capacity Into Frailty Models
  19. Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease
  20. Oral frailty indicators and cardio- and cerebrovascular diseases in older age: A systematic review
  21. Psychiatry and sensation: the epigenetic links
  22. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders
  23. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders
  24. Oral health indicators and bone mineral density disorders in older age: A systematic review
  25. Dietary Intake of Polyphenols and All-Cause Mortality: A Systematic Review with Meta-Analysis
  26. Social Dysfunction and Apathy: Transdiagnostic Domains in Late-Life Cognitive Disorders
  27. Impact of periodontal disease on cognitive disorders, dementia, and depression: a systematic review and meta-analysis
  28. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease
  29. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
  30. Multidimensional complex frailty phenotypes: epidemiological impact of oral frailty in older age
  31. Correction to: Ultra‑processed food consumption and nutritional frailty in older age
  32. Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders
  33. The epigenetics of frailty
  34. The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
  35. The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
  36. Nutritional patterns as machine learning predictors of liver health in a population of elderly subjects
  37. The Relationship between Oral Health-Related Quality of Life and Body Mass Index in an Older Population from Southern Italy: The Salus in Apulia Study
  38. The Relationship between Oral Health‐Related Quality of Life and Body Mass Index in an Older Population from Southern Italy: The Salus in Apulia Study
  39. Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders
  40. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies
  41. Exploring the Association of Burning Mouth Syndrome with Depressive and Anxiety Disorders in Middle-Aged and Older Adults: A Systematic Review
  42. Correction to: Dietary profiling of physical frailty in older age phenotypes using a machine learning approach: the Salus in Apulia Study
  43. Late-Onset Depression but not Early-Onset Depression may Increase the Risk of All-Cause Mortality in Older Age: 8-Year Follow-Up of the Salus in Apulia Study
  44. Processed foods and diet quality in pregnancy may affect child neurodevelopment disorders: a narrative review
  45. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies
  46. Associations of a biopsychosocial frailty phenotype with all-cause dementia, Alzheimer’s disease, vascular dementia, and other dementias: the Italian PRoject on the Epidemiology of Alzheimer’s disease (IPREA)
  47. Effect of Physical Activity Intervention on Gait Speed by Frailty Condition: A Randomized Clinical Trial
  48. Corrigendum: Dietary customs and social deprivation in an aging population from Southern Italy: A machine learning approach
  49. Corrigendum: Liver health and dementia in an Italian older population: Findings from the Salus in Apulia study
  50. Retinal Microvasculature and Neural Changes and Dietary Patterns in an Older Population in Southern Italy
  51. Effect of change of interleukin-6 over time on gait speed response: Results from the lifestyle interventions and independence for elders study
  52. Serum levels of IL-6 are associated with cognitive impairment in the salus in apulia population-based study
  53. Ultra-processed food consumption and nutritional frailty in older age
  54. Biopsychosocial frailty and mild cognitive impairment subtypes: Findings from the Italian project on the epidemiology of Alzheimer's disease (IPREA)
  55. Passive tau-based immunotherapy for tauopathies
  56. Temporomandibular Disorders as Contributors to Primary Headaches: A Systematic Review
  57. Dietary profiling of physical frailty in older age phenotypes using a machine learning approach: the Salus in Apulia Study
  58. Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study
  59. Apolipoprotein E genotype, inflammatory biomarkers, and non-psychiatric multimorbidity contribute to the suicidal ideation phenotype in older age. The Salus in Apulia Study
  60. Clinical Indicators of Oral Frailty: A Domain-Specific Frailty Phenotype
  61. Temporomandibular Disorders as a Risk Factor for Suicidal Behavior: A Systematic Review
  62. Oral frailty indicators to target major adverse health-related outcomes in older age: a systematic review
  63. The challenges of anti-tau therapeutics in Alzheimer disease
  64. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
  65. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease
  66. Motoric Cognitive Risk Syndrome, Subtypes and 8-Year All-Cause Mortality in Aging Phenotypes: The Salus in Apulia Study
  67. Motoric Cognitive Risk Syndrome, Subtypes and 8-year all-cause Mortality in Aging Phenotypes: The Salus in Apulia Study
  68. Dietary Patterns Associated with Diabetes in an Older Population from Southern Italy Using an Unsupervised Learning Approach
  69. Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review
  70. Dietary Customs and Social Deprivation in an Aging Population From Southern Italy: A Machine Learning Approach
  71. Association of Neuroretinal Thinning and Microvascular Changes with Hypertension in an Older Population in Southern Italy
  72. Frailty and outcome after traumatic brain injury
  73. Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study
  74. The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy
  75. Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study
  76. Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
  77. Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study
  78. Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study
  79. Could Epigenetics Play a Role in Suicidal Behavior in Older Age?
  80. Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
  81. Beverages Consumption and Oral Health in the Aging Population: A Systematic Review
  82. How many frailties exist? – Authors' reply
  83. Associations between nutritional frailty and 8‐year all‐cause mortality in older adults: The Salus in Apulia Study
  84. COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy
  85. Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study
  86. Oral frailty and its determinants in older age: a systematic review
  87. Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides
  88. Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy
  89. Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy
  90. Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy
  91. Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study
  92. How gait influences frailty models and health‐related outcomes in clinical‐based and population‐based studies: a systematic review
  93. Vitamin D in the development and progression of alzheimer’s disease: implications for clinical management
  94. Role of plant-based diet in late-life cognitive decline: results from the Salus in Apulia Study
  95. Oral frailty and neurodegeneration in Alzheimer’s disease
  96. Nutritional domains in frailty tools: Working towards an operational definition of nutritional frailty
  97. Late-life depression and its impact on rehabilitation after traumatic injuries
  98. Social Frailty in the COVID-19 Pandemic Era
  99. A multidimensional frailty approach in predicting and preventing dementia
  100. Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy
  101. Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population
  102. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism
  103. Age-related hearing loss and neuropathologic burden
  104. The relationship between epigenetics and microbiota in neuropsychiatric diseases
  105. Age-related hearing loss and speech perception disorder: the broken interface between healthcare professionals and older adults
  106. Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
  107. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
  108. Can pharmacotherapy effectively reduce Alzheimer’s related agitation?
  109. Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy
  110. Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study
  111. The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase
  112. Social determinants of late-life depression epigenetics
  113. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
  114. Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study
  115. Corrigendum to “Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review” Neurosci. Biobehav. Rev. 95 (2018) 480–498
  116. The Challenge of Antidepressant Therapeutics in Alzheimer’s Disease
  117. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging
  118. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?
  119. Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline
  120. Time to test antibacterial therapy in Alzheimer’s disease
  121. Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia
  122. Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging
  123. The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear
  124. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
  125. Disease-modifying therapies for tauopathies: agents in the pipeline
  126. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
  127. Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer’s disease
  128. Understanding frailty to predict and prevent dementia
  129. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
  130. Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke
  131. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
  132. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
  133. The Role of Biomarkers in Psychiatry
  134. Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review
  135. Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life
  136. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
  137. Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study
  138. CYP2D6 genotypes in revolving door patients with bipolar disorders
  139. Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review
  140. Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder
  141. Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention
  142. Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer’s Disease Versus Vascular Dementia
  143. Biopsychosocial Frailty and the Risk of Incident Dementia. The Italian Longitudinal Study of Aging
  144. Comprehensive Geriatric Assessment in Long-Term Care and Nursing Homes
  145. Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging
  146. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
  147. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
  148. Cognitive frailty: a potential target for secondary prevention of dementia
  149. Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry
  150. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review
  151. Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline
  152. An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-term Care Facilities
  153. Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer’s Disease
  154. Emerging biomarkers and screening for cognitive frailty
  155. Genetics of tailored medicine: Focus on CNS drugs
  156. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging
  157. Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association
  158. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?
  159. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
  160. The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes
  161. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
  162. Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders
  163. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?
  164. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
  165. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?
  166. Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder
  167. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?
  168. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
  169. Alternative pharmacological treatment options for agitation in Alzheimer’s disease
  170. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease
  171. Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis
  172. Metabolic Syndrome: Differences between Psychiatric and Internal Medicine Patients
  173. Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity during Working Memory Performance